Document Detail

Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
MedLine Citation:
PMID:  17163268     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Acute myocardial infarction (AMI) is one of the most serious cardiovascular diseases, with acute ST-segment elevation myocardial infarction (STEMI) showing a higher mortality rate than non-ST-segment elevation myocardial infarction (NSTEMI). There is evidence that low-molecular-weight heparin (LMWH) shows greater efficacy than unfractionated heparin (UFH). This open-label, single-centre, randomised study was conducted to compare the efficacy and safety of parnaparin sodium, a LMWH, with UFH in patients with STEMI. PATIENTS AND METHODS: Patients with STEMI were randomised to receive either parnaparin sodium (4250IU aXa subcutaneously every 12 hours for 7 days, initiated 12 hours after thrombolysis) or UFH (100 U/kg intravenous bolus, initiated 12 hours after thrombolytic therapy, followed by 1000 U/hour as a continuous infusion for 3 days, then 7500U subcutaneously every 12 hours for 4 days). Patients were followed up for 45 days (> or =14 days in hospital). RESULTS: In total, 186 patients were randomised to receive parnaparin sodium (n = 96) or UFH (n = 90). A significantly greater reduction in the composite primary endpoint (sum of all deaths, first occurrence of recurrent MI, and first occurrence of emergency revascularisation) was seen with parnaparin sodium compared with UFH at day 45 (27.08% vs 42.22%; p = 0.03). A lower incidence of composite endpoint was seen as early as day 2 with parnaparin sodium, but this did not reach significance versus UFH. The rate of individual endpoint events (death, first occurrence of non-fatal recurrent MI and first occurrence of emergency revascularisation) was lower in the parnaparin sodium group than the UFH group at 2, 7, 14 and 45 days, but the differences were not statistically significant. At day 7, the incidences of any bleeding and heparin-induced thrombocytopenia were also lower in the parnaparin sodium group compared with the UFH group (3.13% vs 10.0%; p = 0.06 and 0% vs 3.33%; p = 0.07, respectively). CONCLUSION: The results of this study indicate that parnaparin sodium is more effective than UFH in reducing composite cardiac events in patients with STEMI following thrombolytic therapy. There was also a lower incidence of bleeding and heparin-induced thrombocytopenia with parnaparin sodium than with UFH. In view of these findings, parnaparin sodium represents an effective, convenient and well tolerated alternative to UFH.
Xu-Kai Wang; Ye Zhang; Cheng-Ming Yang; Yan Wang; Guang-Yao Liu
Related Documents :
10771968 - Kawasaki disease: an update.
8690568 - First case report of spontaneous pulmonary hemorrhage following heparin therapy in acut...
10983738 - Clopidogrel: a review of its use in the prevention of atherothrombosis.
17044808 - The safety and efficacy of aspirin and clopidogrel as a combination treatment in patien...
22449228 - Transient expression of cellular retinol-binding protein-1 during cardiac repair after ...
7748778 - Endovascular intervention in patients with coronary and peripheral arterial disease.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical drug investigation     Volume:  26     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2006  
Date Detail:
Created Date:  2006-12-13     Completed Date:  2007-03-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  341-9     Citation Subset:  IM    
Daping Hospital, Third Military Medical University, Chongqing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / administration & dosage,  adverse effects,  therapeutic use
Blood Coagulation / drug effects
Drug Administration Schedule
Drug Therapy, Combination
Hemorrhage / chemically induced
Heparin / administration & dosage,  adverse effects,  therapeutic use*
Heparin, Low-Molecular-Weight / administration & dosage,  adverse effects,  therapeutic use*
Injections, Intravenous
Injections, Subcutaneous
Middle Aged
Myocardial Infarction / drug therapy*,  physiopathology
Partial Thromboplastin Time / methods
Platelet Count / methods
Thrombocytopenia / chemically induced
Thrombolytic Therapy*
Time Factors
Tomography Scanners, X-Ray Computed
Treatment Outcome
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight; 0/parnaparin; 50-78-2/Aspirin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise he...
Next Document:  Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric...